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Abstract
Background Nutritional status, weight loss and cachexia
have important prognostic implications in patients with
chronic obstructive pulmonary disease (COPD). Body
mass index (BMI) has been implicated in COPD risk
assessment, but information is mostly limited to composite
scores or to patients with stable disease. We aimed to
analyse the association between BMI and mortality in
acute exacerbation of COPD.
Methods This retrospective survey included 968 patients
hospitalized due to acute exacerbation of COPD at the
University Clinic Golnik from February 2002 to June 2007.
Vital status was ascertained with Central Population
Registry, and database was censored on November 1, 2008.
Results Median BMI was 25.08 kg/m
2 (interquartile
range, 21.55–29.05 kg/m
2) and 210 patients (22%) had
BMI<21 kg/m
2. During median follow-up of 3.26 years
(1.79–4.76 years), 430 patients (44%) died. Lowest
mortality was found for BMI 25.09–29.05 kg/m
2.W h e n
divided per BMI decile, mortality was lowest for BMI
25.09–26.56 kg/m
2 (33%). In univariate analysis, BMI per
quartile and BMI per unit increase were predictive for all-
cause mortality. In an adjusted model, BMI per 1 kg/m
2
unit increase was associated with 5% less chance of death
(hazard ratio 0.95, 95% confidence interval 0.93–0.97).
Conclusions Low BMI<21 kg/m
2 is frequent in patients
hospitalized due to acute exacerbation of COPD. Higher
BMI was independently predictive of better long-term
survival. A better outcome in obese patients compared to
normal weight is in contrast to primary prevention data but
concurs with observations of an obesity paradox in other
cardiovascular diseases.
Keywords Chronic obstructive pulmonary disease.Body
mass index.Cachexia.Survival
1 Introduction
Nutritional status, weight loss and cachexia have important
prognostic implications in patients with chronic disease [1,
2]. In contrast to common public beliefs and guidelines for
primary preventive medicine, high body mass index (BMI)
confers protective effects for patients with established
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DOI 10.1007/s13539-011-0023-9chronic diseases such as chronic obstructive pulmonary
disease (COPD), heart failure (HF) and chronic kidney
disease [3–5]. Similar observations have been reported for
other chronic and acute disease conditions which summa-
rized to term reverse epidemiology [6].
Along the natural course of COPD, poor nutritional status,
weight loss and development of cachexia frequently occur [7]
and contribute to excessive morbidity and mortality burden
[8]. In clinical practice, nutritional status is most frequently
estimated by BMI calculation and low BMI has been found
as an independent predictor of increased mortality [3, 7, 8].
Most of the initial studies, however, were conducted in
limited samples or in clinically stable ambulatory patients,
and, therefore, may not reflect the full picture of COPD
patients [8–11]. For hospitalized patients, less information is
available and reports are divergent in their findings. Most of
the studies had relatively short follow-up period, and data
about association between BMI and long-term mortality after
hospitalization for acute exacerbation of COPD is particu-
larly scarce [12–14].
The aim of the present study was therefore to assess the
association between BMI and long-term mortality in COPD
patients after acute deterioration necessitating hospital care.
2 Methods
2.1 Study design
This study used data from a survey which revised all
consecutive discharges from University Clinic Golnik from
February 2002 to June 2007 [15]. Patients discharged with
COPD (J44.0–J44.9 ICD 10 code) as a primary diagnosis
were screened for the analysis. The study protocol was
approved by the National Ethics Committee of Slovenia.
2.2 Patients and data collection
Initial review of medical records identified 1,391 potentially
eligible patients. After verification of COPD as primary
admission cause by an independent review of medical
documentation and availability of required data such as
complete pulmonary function testing and information about
body height and body weight to allow for BMI calculation, we
included 968 patients. Patients’ demographic characteristics,
smoking status, length of hospital stay, concomitant disease,
discharge medication and long-term oxygen therapy (LTOT)
were retrieved from index hospitalization medical records.
2.3 Study endpoints and statistical analysis
The primary outcome of this a priori analysis was all-cause
mortality, which was assessed through the Central Population
Registry, and the database was censored on November 1,
2008. Secondary endpoints included BMI distribution and
relative risk of death across BMI deciles.
Continuous variables are presented as mean values ±
standard deviation or as median (interquartile range—IQR).
Categorical variables are presented as absolute numbers
(%). Differences between the patient subgroups (e.g. per
BMI quartiles) were evaluated using the Student’s t test,
chi-squared test, Mann–Whitney U test and analysis of
variance as appropriate. Kaplan–Meier survival curves were
used to present occurrence of primary endpoints during
follow-up. The difference across BMI quartiles was
compared using the log-rank test. The relationship between
all-cause mortality and BMI per 1 kg/m2 increase (model 1)
or BMI quartiles (model 2) was evaluated with Cox models
of proportional hazards. To identify independent predictors
of mortality, age, gender, Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage, HF, cancer and
asthma were forced into the multivariate model. We report
hazard ratios (HR) and corresponding 95% confidence
intervals (CI). SPSS 16.0 software (SPSS Inc., 2007,
Chicago, IL, USA) was used for statistical calculations.
For all tests, a p value of <0.05 was considered statistically
significant.
3 Results
A total of 968 patients were included in this study, median
BMI was 25.08 kg/m
2 (IQR 21.55–29.05 kg/m
2); 210
patients (22%) had BMI>21 kg/m
2, 294 patients (30%)
were overweight (BMI 25–30 kg/m
2) and 194 patients
(20%) were obese (BMI>30 kg/m
2). Table 1 summarizes
patient characteristics over BMI quartiles. For most
parameters, there were no differences between patient
subgroups. A significant increase was observed for preva-
lence of concomitant asthma and HF and forced expiratory
volume in 1 s (FEV1). By contrast, GOLD stage decreased
over BMI quartiles.
During follow-up (median 3.26 years; range 1.79 to
4.76 years), 430 patients (44%) died. Mortality rates at year 1,
2, and 3 after discharge were 12% (95% confidence interval
[CI] 10-15%), 25% (21-26%), and 32% (29-35%), respec-
tively. Lowest mortality was found for patients in third BMI
quartile (25.09–29.05 kg/m
2) and increased to lowest BMI
quartile—Table 1 and Fig. 1. When patients were divided
per BMI decile, mortality was lowest for those with BMI of
25.09–26.56 kg/m
2 (33%). A linear increase was observed
for patients below optimal BMI decile (a relative risk of 1.94
for patients with BMI<18.42 kg/m
2), whereas risk plateaued
with increasing BMI—Fig. 2.
BMI was associated with all-cause mortality which was
independent of other parameters (Table 2). In univariate
82 J Cachexia Sarcopenia Muscle (2011) 2:81–86survival analysis, BMI per quartile and BMI per unit
increase were predictive for all-cause mortality. The associ-
ations remained significant after adjustment for other
parameters that are known to predict survival in patients
with COPD. In an adjusted model, BMI per 1 kg/m
2 increase
was associated with 5% less chance of death (95% CI 0.93–
0.97). Similarly, patients in two highest BMI quartiles had
48% and 46% less chance of death (95% CI 0.41–0.72)
when compared to patients in lowest BMI quartile.
4 Discussion
This study found that 22% of patients hospitalized due to
acute exacerbation have BMI<21 kg/m
2. We were able to
demonstrate that BMI, either per unit increase or per
quartile, is an independent predictor of long-term mortality.
Importantly, higher BMI was associated with better
survival. Optimal BMI with lowest risk of death was in
the overweight category (BMI of 25.09–26.56 kg/m
2).
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Fig. 1 Kaplan–Meier survival curves per body mass index quartiles and univariate analysis of mortality. HR hazard ratio, CI confidence interval
Table 1 Patient characteristics per body mass index quartiles
All patients
(N=968)
Body mass index
<21.55 kg/m
2
(N=242)
Body mass index
21.55–25.08 kg/m
2
(N=242)
Body mass index
25.09–29.05 kg/m
2
(N=242)
Body mass index
>29.05 kg/m
2
(N=242)
p
Age 70±9 69±9 70±9 70±9 69±9 0.082
Men 700 (72%) 167 (69%) 190 (78%) 174 (72%) 169 (70%) 0.100
Length of stay 12±8 days 12±8 13±10 11±9 12±7 0.351
Mortality 430 (44%) 132 (54%) 123 (51%) 82 (34%) 93 (38%) <0.001
Current smoker 233 (24%) 74 (31%) 60 (25%) 40 (17%) 59 (24%) 0.229
GOLD 2.8±0.9 3.0±0.9 2.8±0.9 2.7±0.8 2.6±0.8 <0.001
FEV1 1,304±577 ml 1,145±554 ml 1,311±620 1,344±555 1,418±545 <0.001
VC 2,885±910 ml 2,843±897 ml 2,998±948 2,889±946 2,810±840 0.116
Asthma 178 (18%) 31 (13%) 39 (16%) 49 (20%) 59 (24%) 0.006
Heart failure 263 (27%) 29 (12%) 54 (22%) 70 (29%) 110 (45%) <0.001
Cancer 108 (11%) 32 (13%) 30 (12%) 24 (10%) 22 (9%) 0.428
SABA 882 (91%) 218 (90%) 225 (93%) 223 (92%) 216 (89%) 0.458
LABA 656 (68%) 159 (66%) 161 (66%) 167 (69%) 169 (70%) 0.693
ICS 627 (65%) 145 (60%) 162 (67%) 153 (63%) 167 (69%) 0.175
Tiotropium 262 (27%) 73 (30%) 62 (25%) 71 (29%) 56 (23%) 0.255
Teophylline 497 (51%) 132 (54%) 132 (54%) 116 (48%) 117 (48%) 0.294
LTOT 194 (20%) 54 (22%) 49 (20%) 38 (16%) 53 (22%) 0.257
FEV1 forced expiratory volume in 1 s, VC vital capacity, SABAs short-acting β2-agonists, LABAs long-acting β2-agonists, ICSs inhaled
corticosteroids, LTOT long-term oxygen treatment, GOLD Global Initiative for Obstructive Lung Disease
J Cachexia Sarcopenia Muscle (2011) 2:81–86 83In patients with COPD, poor nutritional status as
depicted with low BMI is a frequent finding [16–18]. Our
results are confirming previous studies [8, 12] and extend
current knowledge as we evaluated patients with acute
admission due to COPD. Low BMI could also be
suggestive for whole body wasting and occurrence of
cachexia [19, 20]. This generally is a non-reversible
condition, and no effective remedy is available to date
[21, 22].
Acute exacerbation of COPD is a common and serious
situation where hospital admissions are frequent [9]. Low
BMI, along with some other predictors, precipitates need
for hospital care [23]. In contrast to other chronic diseases,
only few strategies are in place to keep COPD patients
away from hospitals and assessment of self-rated health
could drive preventive measures to prevent unnecessary
hospitalizations [24, 25]. This could be particularly relevant
in the context of body size because risk for disability and
poor/fair self-rated health was found to be lowest in
overweight or even obese [26].
Our study has investigated body size in an unselected
population hospitalized due to acute exacerbation of COPD.
Overweight and obesity are firmly established risk factors
for cardiovascular and other diseases, and increased disease
severity of the disease may have been expected in this
COPD population. Importantly, most of the patient charac-
teristics that are available in daily clinical practice were not
different across the BMI spectrum. Also no differences
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Fig. 2 Relative risk for all-cause mortality per body mass index deciles (body mass index 25.09–26.56 kg/m
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Univariate Multivariate
Model 1 Model 2
Body mass index [per 1 kg/m
2] 0.95 [0.94–0.97] 0.95 [0.93–0.97] NA
Body mass index
<21.55 kg/m
2 Reference NA reference
21.55–25.08 kg/m
2 0.81 [0.63–1.04] NA 0.82 [0.64–1.06]
25.09–29.05 kg/m
2 0.53 [0.40–0.70] NA 0.52 [0.39–0.69]
>29.05 kg/m
2 0.58 [0.44–0.75] NA 0.54 [0.41–0.72]
Age [per 1 year] 1.04 [1.03–1.05] 1.03 [1.02–1.04] 1.03 [1.02–1.04]
Gender [male vs female] 0.90 [0.73–1.12] 0.87 [0.70–1.09] 0.87 [0.70–1.09]
GOLD stage I Reference Reference Reference
GOLD stage II 1.29 [0.75–2.20] 1.13 [0.66–1.95] 1.12 [0.65–1.93]
GOLD stage III 1.41 [0.83–2.40] 1.04 [0.60–1.79] 1.06 [0.62–1.83]
GOLD stage IV 2.82 [1.66–4.80] 2.07 [1.20–3.56] 2.11 [1.23–3.63]
Heart failure 1.60 [1.31–1.95] 1.72 [1.39–2.14] 1.65 [1.33–2.05]
Cancer 1.80 [1.37–2.36] 1.60 [1.21–2.11] 1.54 [1.17–2.03]
Asthma 0.61 [0.47–0.80] 0.75 [0.57–0.98] 0.75 [0.57–0.98]
Table 2 Cox proportional
hazard models for all-cause
mortality
Data are presented as hazard
ratios and 95% confidence
intervals
GOLD Global Initiative for
Obstructive Lung Disease, NA
not applicable
84 J Cachexia Sarcopenia Muscle (2011) 2:81–86were found for COPD specific treatments. The prognosis
was predicted by BMI independently of other established
mortality predictors with better survival observed in those
patients who were overweight and obese. Implications of
our results are relevant for clinical practice because BMI is
an easily accessible parameter, even in acutely deteriorated
patients. For COPD, several scoring systems to predict
prognosis were developed. The BODE score includes body-
mass index (B), the degree of airflow obstruction (O) and
dyspnea (D), and exercise capacity (E). The BODE
composite score [23] is allegedly the most frequently used
in everyday practice but it is primarily limited to patients
with clinically stable disease as seen in outpatient setting.
Due to its availability and clinical importance, the BMI has
also been included in other scoring systems in patients with
COPD [27]. Overall, the low BMI is included in the scoring
systems to predict outcome in COPD patients as managed
by primary and secondary care physicians [23, 27]. Our
study confirms increased risk in patients with low BMI. But
more importantly, we show that overweight and moderate
obesity are not associated with increased mortality. Further,
during acute exacerbation, however, some of the score
components (e.g. forced expiratory volume in 1 second,
dyspnoea score) may be particularly vulnerable to short-
term changes which limit the applicability of risk assess-
ment during patient deterioration. Our results demonstrated
that BMI, even on top of other recognized risk stratificators
that are reliably accessible during course of transient
clinical deterioration, is predictive of all-cause mortality in
patients admitted due to COPD exacerbation. Although
retrospective in design, our study has relevant advantages
over previous reports. We have included a large sample
of patients with reliable diagnosis of COPD, and we
have followed them for long-term outcome. Importantly,
we have included only patients already experiencing
worsening which necessitated hospital admission. Such
an event is a relevant point to both patient and caring
physician in a patient’s course of disease to predict future
disease progression and to re-consider therapeutic strate-
gies [25, 28]. In an era of complex patient assessment,
future studies need to look into composite scores including
cardiovascular therapy and treatment as well as laboratory
parameters beyond COPD [29]. This could identify novel
therapeutic strategies either to prevent patient deterioration
or to improve rehabilitation and outcome once clinical
condition has worsened [30–32]. It is important to stress
that management strategies have to shift beyond the
symptom relief interventions [33, 34] and to assess the
global patient situation beyond COPD, where concomitant
d i s e a s em a yp l a yad e c i s i v er o l e[ 2, 35]. A tailored
approach accounting for patient complexity and disease
severity, preferably in an outpatient setting [36], could
prove as particularly advantageous.
4.1 Limitations
This study has to be interpreted in view of certain
limitations. Through selected methodology, we were unable
to control for potential effects of parameters beyond the
included variables thus there exists a risk of residual
confounding by additional variables and co-morbidities
beyond the study design. It is important to notice that our
findings are based upon index hospitalization information
which was not controlled for any changes through the
follow-up period. This limitation, however, is driven per
study design and is shared with many previous publications
[12–14].
4.2 Clinical implications
BMI is an easily accessible parameter which carries
important information for patient assessment and risk
stratification. This is particularly important in the presence
of chronic disease like COPD. In patients experiencing
acute exacerbation of COPD, assessment of functional
parameters like dyspnoea, exercise capacity and pulmonary
function may be of limited value for long-term risk
assessment which could importantly impact risk stratifica-
tion. Our results, along with some of previous studies [3, 7–
15], suggest that BMI calculation carries a potential to
identify patient at risk of poor prognosis. This enables the
clinicians to identify patients at risk and to plan future
therapeutic efforts to prevent body wasting and to improve
prognosis for patients with COPD [37, 38].
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